Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The NF-kappaB transcription factor is normally transiently activated by proinflammatory cytokines and bacterial
lipopolysaccharide
(
LPS
); however, persistent NF-kappaB activation is commonly observed in inflammatory disease and malignancy. The ubiquitin editing enzyme A20 serves an essential role in the termination of TNF-alpha- and
LPS
-mediated NF-kappaB signaling by inactivating key signaling molecules. However, little is known about how A20 is regulated and if other molecules play a role in the termination of NF-kappaB signaling. Here we demonstrate that
Tax1-binding protein 1
(
TAX1BP1
) is essential for the termination of NF-kappaB and JNK activation in response to TNF-alpha, IL-1 and
LPS
stimulation. In
TAX1BP1
-deficient mouse fibroblasts, TNF-alpha-, IL-1- and
LPS
-mediated IKK and JNK activation is elevated and persistent owing to enhanced ubiquitination of RIP1 and TRAF6. Furthermore, in the absence of
TAX1BP1
, A20 is impaired in RIP1 binding, deubiquitination of TRAF6 and inhibition of NF-kappaB activation. Thus,
TAX1BP1
is pivotal for the termination of NF-kappaB and JNK signaling by functioning as an essential regulator of A20.
...
PMID:Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and LPS-mediated NF-kappaB and JNK signaling. 1770 91